Related Experiment Video
Updated: Aug 4, 2026

Experimental Metastasis Assay
Published on: August 24, 2010
Personalized identification and characterization of genome-wide gene expression differences between patient-matched
Theresa Kraft1, Konrad Grützmann1, Matthias Meinhardt2
1Institute for Medical Informatics and Biometry (IMB), Carl Gustav Carus Faculty of Medicine, Technische Universität Dresden, Fetscherstr. 74, 01307, Dresden, Germany.
Abstract:
Melanoma is the most serious type of skin cancer that frequently spreads to other organs of the human body. Especially melanoma metastases to the brain (intracranial metastases) are hard to treat and a major cause of death of melanoma patients. Little is known about molecular alterations and altered mechanisms that distinguish intra- from extracranial melanoma metastases. So far, almost all existing studies compared intracranial metastases from one set of patients to extracranial metastases of an another set of melanoma patients. This neglects the important facts that each melanoma is highly individual and that intra- and extracranial melanoma metastases from the same patient are more similar to each other than to melanoma metastases from other patients in the same organ. To overcome this, we compared the gene expression profiles of 16 intracranial metastases to their corresponding 21 patient-matched extracranial metastases in a personalized way using a three-state Hidden Markov Model (HMM) to identify altered genes for each individual metastasis pair. This enabled three major findings by considering the predicted gene expression alterations across all patients: (i) most frequently altered pathways include cytokine-receptor interaction, calcium signaling, ECM-receptor interaction, cAMP signaling, Jak-STAT and PI3K/Akt signaling, (ii) immune-relevant signaling pathway genes were downregulated in intracranial metastases, and (iii) intracranial metastases were associated with a brain-like phenotype gene expression program. Further, the integration of all differentially expressed genes across the patient-matched melanoma metastasis pairs led to a set of 103 genes that were consistently down- or up-regulated in at least 11 of the 16 of the patients. This set of genes contained many genes involved in the regulation of immune responses, cell growth, cellular signaling and transport processes. An analysis of these genes in the TCGA melanoma cohort showed that the expression behavior of 11 genes was significantly associated with survival. Moreover, a comparison of the 103 genes to three closely related melanoma metastasis studies revealed a core set of eight genes that were consistently down- or upregulated in intra- compared to extracranial metastases in at least two of the three related studies (down: CILP, DPT, FGF7, LAMP3, MEOX2, TMEM119; up: GLDN, PMP2) including FGF7 that was also significantly associated with survival. Our findings contribute to a better characterization of genes and pathways that distinguish intra- from extracranial melanoma metastasis and provide important hints for future experimental studies to identify potential targets for new therapeutic approaches.
Insights
This study reveals molecular differences between brain and other melanoma metastases. Intracranial melanoma showed a brain-like gene expression and downregulated immune signaling, offering targets for new treatments.
Area of Science:
- Oncology
- Molecular Biology
- Genomics
Background:
- Melanoma is a severe skin cancer with high mortality, often due to brain metastases (intracranial metastases).
- Understanding molecular differences between intracranial and extracranial metastases is crucial for treatment, yet studies often lack patient-matched comparisons.
- Individual melanoma tumors exhibit unique molecular profiles, necessitating personalized analysis of metastasis origins.
Purpose of the Study:
- To identify molecular alterations distinguishing intracranial from extracranial melanoma metastases on a patient-matched basis.
- To uncover specific gene expression patterns and signaling pathways altered in brain metastases.
- To identify potential therapeutic targets for melanoma brain metastases.
Main Methods:
- Compared gene expression profiles of 16 intracranial metastases with 21 patient-matched extracranial metastases.
- Utilized a three-state Hidden Markov Model (HMM) for personalized analysis of metastasis pairs.
- Integrated differentially expressed genes across patients to identify consistently altered genes and pathways.
Main Results:
- Identified significantly altered pathways including cytokine-receptor interaction, calcium signaling, and PI3K/Akt signaling.
- Observed downregulation of immune-relevant signaling pathway genes in intracranial metastases.
- Detected a 'brain-like' phenotype gene expression program in intracranial metastases, with 103 consistently altered genes identified across patients.
- Found 11 genes significantly associated with survival in the TCGA melanoma cohort.
- Identified a core set of eight genes consistently altered in intracranial versus extracranial metastases across multiple studies, including FGF7, associated with survival.
Conclusions:
- Melanoma brain metastases exhibit distinct molecular characteristics compared to extracranial metastases, including altered signaling pathways and immune response gene expression.
- The identified 'brain-like' phenotype and specific gene signatures provide insights into melanoma brain metastasis development.
- This research highlights potential therapeutic targets and emphasizes the importance of personalized analysis in understanding metastasis heterogeneity.
Related Concept Videos
Pleiotropy
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

